<DOC>
	<DOCNO>NCT02896582</DOCNO>
	<brief_summary>This study multicentric , single arm phase II trial evaluate efficacy upfront obinutuzumab mantle cell lymphoma patient treat Cisplatinum-Cytarabine-Dexamethasone ( DHAP ) follow autologous transplantation plus obinutuzumab maintenance Molecular Residual Disease ( MRD ) drive maintenance</brief_summary>
	<brief_title>Efficacy Upfront Maintenance Obinutuzumab Mantle Cell Lymphoma Treated DHAP MRD Driven Maintenance</brief_title>
	<detailed_description>Patients recruit 2 year . They must histologically prove diagnosis mantle cell lymphoma , age 18 65 year time registration . Patients must eligible autologous transplant previously treat lymphoma inclusion . Patients receive 4 cycle Obinutuzumab ( GA101 ) Cisplatinum-Cytarabine-Dexamethasone ( GA-DHAP ) every 21 day follow Autologous Stem Cell Transplant ( ASCT ) use GA101-Carmustine- Etoposide- Cytarabine- Melphalan ( GA-BEAM ) condition regimen plus Obinutuzumab maintenance 3 year Obinutuzumab maintenance demand accord MRD status . Stem cell collect cycle 3 and/or 4 GA-DHAP .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Age ≥ 18 age ≤ 65 Histologically confirm ( accord World Health Organization ( WHO ) classification ) mantle cell lymphoma . The diagnosis confirm phenotypic expression CD5 , CD20 cyclin D1 ( 11 ; 14 ) translocation . Bone marrow aspiration perform inclusion MRD analyse Eligible autologous stem cell transplant Previously untreated MCL Stage Ann Arbor IIIV need treatment Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Life expectancy 3 month Written inform consent Patient affiliate social security system Severe cardiac disease : York Heart Association ( NYHA ) grade 34 Impaired liver ( ALanine Amino Transferase ( ALAT ) /ASparagin Amino Transferase ( ASAT ) ≥ 2.5 Upper Limit Normal ( ULN ) , bilirubin ≥ 1.5 ULN ) , renal ( calculated creatinine clearance &lt; 50 ml/min ) organ function interfere treatment , related lymphoma . History chronic liver disease Hepatic venoocclusive disease sinusoidal obstruction syndrome Any follow laboratory abnormality , result BM infiltration : Absolute Neutrophils Count ( ANC ) &lt; 1,500 /mm3 ( 1.5 x 109/L ) Platelet count &lt; 75,000/mm3 ( 75 x 109/L ) Pregnancy/Nursing mother Fertile men woman childbearing potential unless : surgically sterile ≥ 2 year onset menopause willing use highly effective contraceptive method Patients malignancy treat curative intent , unless malignancy remission without treatment ≥ 5 year prior enrollment . Patients history curatively treat basal squamous cell carcinoma melanoma skin situ carcinoma cervix eligible . Known seropositivity Human Immunodeficiency Virus ( HIV ) , Hepatitis C Virus ( HCV ) active infection uncontrolled treatment . Viral infection hepatitis B virus ( HBV ) define hepatitis B surface antigen ( HBsAg ) positive and/or Hepatitis B core antibody ( antiHBc ) positive Note : Patients immune due hepatitis B vaccination natural infection ( HBs Ag antiHBc negative , antiHBs positive ) eligible . But patient immune due hepatitis B natural infection consult liver disease expert start treatment monitor manage follow local medical standard prevent hepatitis reactivation Prior history Progressive Multifocal Leukoencephalopathy ( PML ) Vaccination live vaccine minimum 28 day prior inclusion ( Prolonged B cell depletion ) History severe allergic anaphylactic reaction humanize murine monoclonal antibody . Known sensitivity allergy murine product Psychiatric illness condition could interfere ability understand requirement study . Person deprive his/her liberty judicial administrative decision Person hospitalize without consent Adult person legal protection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>